strategic development of patient and public involvement in a major comparative effectiveness...
DESCRIPTION
Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UKTRANSCRIPT
![Page 1: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/1.jpg)
26 June 2012
Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK
NIHR Evaluation, Trials and Studies Coordinating Centre
Alison Ford, Ruairidh Milne, Elaine Williams
![Page 2: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/2.jpg)
![Page 3: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/3.jpg)
Health Technology Assessment Programme
• Established 1993, central government funded• Managed by NIHR Evaluation Trials & Studies
Coordinating Centre• Commissions and manages health research• Primary research and evidence synthesis• Value for money
![Page 4: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/4.jpg)
Health Technology Assessment Programme
Findings published in HTA journal
2010 Impact Factor 4.197: in the top 10% of medical and
health-related journals
![Page 5: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/5.jpg)
“People-focused research in the NHS simply cannot be delivered without the involvement of patients and the public.
No matter how complicated the research or how brilliant the researcher, patients and the public always offer unique, invaluable insight.”
Professor Dame Sally C Davies
Chief Medical Officer for England, Department of Health
![Page 6: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/6.jpg)
PPI established within HTA
• HTA website for topic identification ideas
• Referees for commissioning briefs
• Panel members at prioritisation stage
• Referees for full proposals
But......‘an uneven spread’
Moran R, Davidson P. An uneven spread: a review of public involvement in the National Institute of Health Research's Health Technology Assessment program. International Journal of Technology Assessment in Health Care, 2011;27:343-7.
![Page 7: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/7.jpg)
Rapid growth of NETSCC from 2008
• New programmes, different types of research• Broader portfolio• More identification, prioritisation and funding
decisions• More applicants and studies to monitor• More outputs to publish and disseminate• New opportunities for involvement• More consistent and strategic approach needed
![Page 8: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/8.jpg)
Developing the PPI strategic approach
• Formal project structure• Brief literature review• Workshops with PPI lead staff• Consultation with public contributors• One-to-one consultation with programme directors • Consultation with & support from INVOLVE • Agreement secured with NETSCC Board
![Page 9: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/9.jpg)
The PPI framework
• What NETS programmes must do• What researchers should do• What public contributors can do• Across whole research cycle• Effective PPI activity• Internal research management• Design and conduct in studies
![Page 10: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/10.jpg)
![Page 11: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/11.jpg)
![Page 12: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/12.jpg)
![Page 13: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/13.jpg)
![Page 14: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/14.jpg)
![Page 15: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/15.jpg)
![Page 16: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/16.jpg)
![Page 17: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/17.jpg)
![Page 18: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/18.jpg)
![Page 19: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/19.jpg)
What have we gained?(1) How involvement has changed• Larger, more diverse range of people involved• More information recorded about individual public
contributors’ experience, understanding & interest• Very high rate of public reviewer input to commissioning
briefs and proposals• Public members on boards and panels of all programmes• Research applications show commitment to involvement of
patients and the public in design and conduct of studies• Public involvement more actively monitored in progress of
studies
![Page 20: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/20.jpg)
What have we gained?(2) How NETSCC has changed
• A real commitment to PPI• PPI woven into language of the organisation• Staff knowledge, skills & behaviour• Clear policy and support processes• Boards and panels see public contribution
differently• A team approach to strategic development of
PPI
![Page 21: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/21.jpg)
Key learning for other organisations• It is possible to involve patients and the public in every
aspect of research management• Genuine Board-level commitment is essential• Build components of the involvement approach into the
organisation’s strategy• Networking across the health research community will
bring about valuable contacts and economy of scale • Involved volunteers are not ‘free’• Cultural change takes time
![Page 22: Strategic development of patient and public involvement in a major comparative effectiveness research programme in the UK](https://reader033.vdocuments.net/reader033/viewer/2022060110/555ddf83d8b42a192c8b4c0f/html5/thumbnails/22.jpg)
Any questions…?
Alison Ford
Public and Patient Involvement Manager
t: +44 (0) 23 8059 7435
f: +44 (0) 23 8080 5639
NIHR Evaluation, Trials and Studies Coordinating Centre
(NETSCC) part of the National Institute of Health Research (NIHR)
Alpha House, University of Southampton Science Park,
Southampton SO16 7NS
w: www.netscc.ac.uk
Acknowledgement:
This activity was funded by the NIHR and carried out by the Evaluation, Trials and Studies Coordinating Centre at the University of Southampton.